Navigation Links
Statement from the Consumer Healthcare Products Association on Mississippi Bill that Seeks to Make Cold, Allergy Medicines Containing Pseudoephedrine Prescription-Only

Majority of Mississippi voters support e-tracking as better solution

WASHINGTON, Jan. 28 /PRNewswire-USNewswire/ -- The following is a statement by Linda A. Suydam, D.P.A., president of the Consumer Healthcare Products Association (CHPA):

"Today, the Mississippi House of Representatives passed a bill without listening to any testimony that, if it becomes law, will greatly limit how cold and allergy sufferers access some of their medicines. The legislation would require law-abiding families to obtain a doctor's prescription for pseudoephedrine- (PSE-) containing medicines rather than simply asking for these medications at the pharmacy or service counter. Mississippi lawmakers seem prepared to impose this burden on Mississippians, even though there is a better solution.

"Mississippi's voters agree this is not the right way to address meth. As states continually find themselves in dire financial situations, policy makers must balance efforts to regulate ingredients used to create meth with the public health and economic consequences of restricting access to important cold and allergy medications. Electronic tracking is one such solution that eight other states have adopted to fight domestic meth production while maintaining consumer over-the-counter access to these products.

"An e-tracking system is a tool that law enforcement and pharmacists can put in place to stop the sale of illegal amounts of PSE as set forth by the Combat Meth Act. With this real-time tracking system, states can also link up with other states to track cross-border sales. For instance, neighboring Louisiana has plans to implement e-tracking starting in March. Additionally, e-tracking would be implemented at no cost to the state; the makers of PSE-containing products would purchase and maintain the system for Mississippi.

"A CHPA-sponsored survey conducted by David Binder Research this month* found that almost two-thirds of Mississippi voters surveyed (N=350) feel making common cold and allergy medications containing pseudoephedrine available by prescription only would be a big mistake, placing a heavy and unnecessary new burden on law-abiding people, significantly increasing consumer costs, and hurting the state's own finances at the worst possible time.

"Among other findings:

  • 61 percent of those surveyed would oppose laws that would require these medications be sold only by prescription.
  • 74 percent of those surveyed agree that an Rx-only requirement would create an 'unnecessary burden' for law-abiding citizens.
  • And 59 percent of those surveyed indicate they feel the legislative train is speeding forward too fast, agreeing 'before my state's lawmakers enact a new law, they should study the economic impact and societal burden a prescription law would pose.'

"This House bill was passed before hearing any testimony or listening to the concerns of constituents. We  urge the state legislature to assess the deep burdens of this bill and the proven alternative of e-tracking before placing such serious and costly restriction on law-abiding Mississippians. "

CHPA is the 129-year-old-trade association representing U.S. manufacturers and distributors of over-the- counter medicines and nutritional supplements.

SOURCE Consumer Healthcare Products Association



SOURCE Consumer Healthcare Products Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Statement from RC Cancer Centers Regarding News Story on Radiation Oncology
2. Statement From the American Health Care Association and National Center for Assisted Living in Anticipation of President Obamas State of the Union Address
3. SEIU-UHW Statement on Kaiser Union Election in Southern California
4. Operation Rescues Advisory Board Issues Statement on Mr. Terrys Extremism
5. Statement: Helping the UN Help Haiti
6. Pelosi Statement on New Report That Health Reform Will Create 4 Million More Jobs Over the Next Decade
7. Statement by Blue Shield of California CEO Bruce Bodaken Regarding the Groundbreaking for the Family Violence Prevention Funds International Center
8. Statement of US Secretary of Labor Hilda L. Solis on December 2009 employment numbers
9. FRC Statement on the Christmas Eve Passage of the Health Care Reform Bill
10. Statement from Larry Minnix, CEO, American Association of Homes and Services for the Aging On the Senates Passage of Health Reform Legislation
11. PhRMA Statement on Senate Health Care Reform Bill
Post Your Comments:
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, ... biologics, consumer health and global clinical supply services, today announced that Dr. Christine ... Supply East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Preparing for ... p.m. – 3:00 p.m. EST, , FDA has long asserted that ... regulations apply to performing the tests and do not meet the device regulations. , ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Bolier Reactor System. Brillouin is the developer of renewable energy technologies capable of ... nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler System reactor ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... gather to share their knowledge and experiences at a live taping of the ... Ruesch Center for the Cure of Gastrointestinal Cancers 2015 Symposium at Georgetown University ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... LYON , Frankreich, November 25, 2015 ... hat heute bekanntgegeben, dass sie eine Lizenz für das ... Inserm, Poxel, CNRS, UCBL und ENS-Lyon innehaben, an Enyo ... 2009 von FUI AAP8 ins Leben gerufenen und von ... NATHEB-Programms wurde FXR als ein Behandlungsziel für HBV identifiziert, ...
(Date:11/24/2015)... WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: ... technology platform company serving the pharmaceutical, biotechnology, and medical ... and the United States , ... shareholders held today, the Company,s shareholders voted in favor ... announced agreement and plan of merger (the "Merger Agreement") ...
(Date:11/24/2015)... BOULDER, Colo. , Nov. 24, 2015 /PRNewswire/ ... announced that its Chief Executive Officer, Ron ... Annual Healthcare Conference in New York.  The public ... a webcast on the Array BioPharma website.Event:Piper Jaffray ... OfficerDate:  , Wednesday, December 2, 2015Time:1:30 p.m. Eastern ...
Breaking Medicine Technology: